Enhanced Cellular Transduction of Nanoparticles Resistant to Rapidly Forming Plasma Protein Coronas by Blokpoel Ferreras, Lia A. et al.
www.adv-biosys.com
2000162 (1 of 16) © 2020 The Authors. Published by Wiley-VCH GmbH
Full PaPer
Enhanced Cellular Transduction of Nanoparticles Resistant 
to Rapidly Forming Plasma Protein Coronas
Lia A. Blokpoel Ferreras, Daniel Scott, Saul Vazquez Reina, Paul Roach, 
Teobaldo E. Torres, Gerardo F. Goya, Kevin M. Shakesheff, and James E. Dixon*
DOI: 10.1002/adbi.202000162
physical properties suitable for directly 
targeting therapeutic sites using magnetic 
fields.[2] Furthermore, the ability of MNPs 
(a subtype being superparamagnetic 
iron oxide NPs; SPIONs) to efficiently 
convert magnetic energy into thermal 
energy, makes them a focus of interest for 
use in hyperthermia-based cell ablation 
anticancer therapies (such as Magforce 
Nanotechnologies AG).[3–6] Other relevant 
applications include imaging (including 
a focus on regenerative medicine), tissue 
engineering, for mechanical stimula-
tion for cell differentiation in vivo[7–17] 
and, most recently, their use as synthetic 
enzymes in biocatalytic processes.[18]
Targeted delivery strategies for MNPs 
have been developed toward specific- or 
overexpressed receptors on diseased cells 
by functionalizing the NP surface with 
proteins, antibodies, or other biomolecules 
as targeting ligands. These strategies effi-
ciently enhance NP delivery to the target 
cells in vitro; however, there is mounting 
evidence that targeting ability of function-
alized NPs disappears when placed in an 
in vivo biological environment.[19–21]
It is now well established that when any material surface 
encounters a biological system, interactions occur between 
the material and the system components (i.e. proteins, lipids, 
DNA) forming a layer termed the protein corona. The protein 
corona defines the biological identity of the particle or surface, 
and has proven to be an obstacle in the past for effective tar-
geted delivery of ligands, since it affects the physicochemical 
Nanoparticles (NPs) are increasingly being developed as biomedical plat-
forms for drug/nucleic acid delivery and imaging. However, in biological 
fluids, NPs interact with a wide range of proteins that form a coating known 
as protein corona. Coronae can critically influence self-interaction and binding 
of other molecules, which can affect toxicity, promote cell activation, and 
inhibit general or specific cellular uptake. Glycosaminoglycan (GAG)-binding 
enhanced transduction (GET) is developed to efficiently deliver a variety of 
cargoes intracellularly; employing GAG-binding peptides, which promote cell 
targeting, and cell penetrating peptides (CPPs) which enhance endocytotic 
cell internalization. Herein, it is demonstrated that GET peptide coatings can 
mediate sustained intracellular transduction of magnetic NPs (MNPs), even 
in the presence of serum or plasma. NP colloidal stability, physicochemical 
properties, toxicity and cellular uptake are investigated. Using label-free snap-
shot proteomics, time-resolved profiles of human plasma coronas formed on 
functionalized GET-MNPs demonstrate that coronae quickly form (<1 min), 
with their composition relatively stable but evolving. Importantly GET-MNPs 
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GAG-binding activities. Understanding how NPs interact with biological sys-
tems and can retain enhanced intracellular transduction will facilitate novel 
drug delivery approaches for cell-type specific targeting of new nanomaterials.
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1. Introduction
Nanoparticles (NPs) are broadly used in biomedical and bio-
technological applications due to their physical properties.[1] 
Their small size and high surface area makes NPs ideal carriers 
(for example, for macromolecular nucleic acids and small mole-
cule drugs), and magnetic variants (magnetic NPs; MNPs) have 
© 2020 The Authors. Published by Wiley-VCH GmbH. This is an open 
access article under the terms of the Creative Commons Attribution 
License, which permits use, distribution and reproduction in any 
medium, provided the original work is properly cited.
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properties of the particles and the availability of targeted ligand 
interaction.[22–26]
We have developed a peptide-based system, which can be 
grafted onto the surface of MNPs, specifically here dextran-
coated SPIONs. This system is termed glycosaminoglycan 
(GAG)-binding enhanced transduction (GET) and its effi-
ciency relies on the synergistic combination of a cell pen-
etrating peptide (CPP) and a membrane docking peptide 
to heparan sulfate GAGs.[27] Importantly, we have demon-
strated that these peptides can be employed to deliver MNPs 
in vitro,[9,27] can be used in vivo for gene therapy,[28,29] and 
for delivering recombinant proteins for tissue engineering 
applications.[30–32]
In this study, we have characterized and quantified the phys-
icochemical properties and delivery of GET peptide-coated 
MNPs (GET–MNPs) to mammalian cells in vitro. GET electro-
static coating (we term “complexation”) was able to efficiently 
enhance particle uptake in protein-free, and in serum and 
plasma-rich conditions. As this appeared to conflict with pub-
lished examples that use cell membrane targeting of NPs,[19–21] 
we investigated the structure and complexity of our MNP inter-
face within these biological microenvironments. We examined 
protein corona density and complexity formed on GET–MNPs 
over time as well as any pathobiological effects. We demon-
strate that GET–MNPs are resistant to the inhibitory effect of 
serum- or plasma-coronas, suggesting that our system can be 
used in such complex biological microenvironments for appli-
cation of nanotechnology. Furthermore, the complexity of the 
coronae can be linked to the GET peptides ability to interact 
with GAG-associated proteins, and there were no apparent 
effects on hemotoxicity. Our study therefore is significant in 
understanding how protein–particle interactions can affect tar-
geting, uptake, and biocompatibility when exploiting nanotech-
nologies for nanomedicine.
2. Results
2.1. Facile Production of Monodispersed Electrostatically 
Coupled GET-Coated MNPs
Currently, dextran-coated MNPs or SPIONs (containing iron 
oxide cores) are being translated for a wide number applica-
tions in biomedicine.[7,33–35] We employed commercially avail-
able dextran-COOH-coated SPIONS (Nanomag-D, 250  nm, 
Micromod) for these studies. These particles can be captured 
by use of a static magnet and have been previously used 
for hyperthermia-mediated cell death and cell tracking in 
vivo.[9,36] Transmission electron microscopy (TEM) analysis 
of MNPs in the colloidal dispersion showed a multicrystal-
lite structure of the NPs, having irregular shape and average 
size of 133  nm ± 38  nm (Figure  1a; Figure S1, Supporting 
Information). Thermogravimetric analysis (TGA) showed a 
percentage of organic phase of 24.4 ± 2.4%, confirming the 
presence of dextran in the particles (Figure S2 and Table S1, 
Supporting Information). Data obtained with these MNPs 
was highly reproducible, negating the often confounding 
factor of heterogeneity in commercially obtained MNPs. 
As we were confident in the source and properties of these 
MNPs, we employed them throughout our studies. Previ-
ously, we have shown that by simple co-incubation of GET 
peptides with these MNPs, we could enhance intracellular 
uptake of MNPs into mammalian cells.[9,27] Our system relies 
on electrostatic interaction of the positive GET peptides and 
negative cargo for nucleic acid delivery applications.[27–29] 
These dextran-coated MNPs are negatively charged and 
therefore hypothesized to directly interact with GET pep-
tides through electrostatic binding. The GET peptide, P21-8R 
(Figure  1b), is a positively charged l-amino acid (isoelectric 
point pI ≈12),[27] so in order to confirm electrostatic interac-
tions between GET and MNPs, we studied the zeta potential 
of MNPs at increasing GET concentrations (Figure  1c). The 
shift in zeta potential of MNPs (−26.2  mV) compared with 
GET functionalized particles at 4 and 8 nmol mg−1 (11.7 and 
20.3  mV, respectively) indicates strong electrostatic interac-
tion between the dextran-coated particles and the positively 
charged GET, which was proportional to the peptide’s con-
centration. Dynamic light scattering (DLS) analysis showed 
particles in the monodisperse range after functionalization 
with 4–8 nmol mg−1 of GET (Figure 1d and Table 1) with no 
significant changes from particle size distribution compared 
to noncomplexed MNPs.[37]
2.2. GET Peptides Are Absorbed to MNPs and Change 
Conformation
Upon adsorption onto a surface, protein molecules can 
experience a change in conformation and/or orientation in 
search of the most energetically stable arrangement. Driven 
by hydrophobicity and charged group interaction these struc-
tural changes can impact on protein–substrate interactions 
and thereby reduce their availability/bioactivity.[38–40] It was 
therefore paramount to understand the degree of change 
in the peptide structure upon adsorption. Protein structure 
can be studied through the analysis of their amide I band, 
which provides a very strong adsorption by infrared spec-
troscopy. This band can be deconvoluted in order to quan-
tify secondary structure components (Figure S3, Supporting 
Information).[41–43] GET significantly loses alpha-helical struc-
ture in favor of beta-sheet component (alpha-helix fraction 
decreases from 0.26 to 0.22, p < 0001, n = 9; beta-sheet frac-
tion increases 0.29 to 0.32, p < 0.0001, n = 9). These changes 
suggest a certain degree of denaturation of the original GET 
peptide secondary structure on interaction with MNPs. The 
increase of beta-sheet component suggests a higher coordi-
nation of the different subunits of the molecule (containing 
the lysine-rich P21 peptide GAG-binding domain and octo-
arginine 8R CPP component). A change in structure toward 
beta-sheet at the expense of alpha-helix has been observed by 
others investigating protein–NP interaction,[43] highlighting 
the structural change in association with the MNPs surface. 
The differences on GET secondary structure when incubated 
with MNPs further reinforce the DLS and zeta potential data 
in confirming the direct interaction of the GET peptide with 
MNPs.
The complexity of any protein adsorption process makes 
development of models that account for all the possible 
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binding interactions and phenomena involved very difficult. 
Current models to describe protein adsorption present cer-
tain limitations, however, they can be used with caution to 
estimate parameters that are relevant for particle formula-
tion.[44] A red fluorescent (TAMRA-tag grafted on an N-ter-
minal cysteine group in P21-8R) version of GET (termed 
GET-T) was used to assess interaction by binding isotherms 
of peptide to MNPs with fluorometry. In this context, Lang-
muir’s approximation (Equation 1) was used to fit the adsorp-
tion isotherms due to its ability to estimate relevant param-
eters such as maximum concentration of bound protein in 
a monolayer formation (Smax) as well as the equilibrium 
constant for the adsorption (K).[44–46] We plotted adsorbed 
Figure 1. GET peptides bind to MNPs through electrostatic interaction. a) Representative TEM image of the Micromod Nanomag-D 250 nm particles 
(MNPs) showing the size of the magnetic core is about 100 nm in diameter. Scale bar: 100 nm. b) GET peptide, P21-8R, primary structure, and amino 
acid sequence. GAG-binding domain represented in green and cell penetrating peptide domain (CPP) represented in red. c) Zeta potential distribu-
tion of particles 50 µg incubated with increasing concentrations of GET (GET concentration expressed as nmol GET mg−1 of particles). Zeta potential 
was measured in water. The shift in zeta potential indicates the interaction of GET with MNPs (n = 6 independent repeats, 3 subruns per repeat). 
d) Apparent diameter of the particles obtained by DLS for 50 µg mL−1 of MNPs incubated with increasing concentrations of GET (GET concentration 
expressed as nmol GET mg−1 of particles). DLS measurements were done in water (n = 6 independent repeats, 3 subruns per repeat, error bars in the 
close-up plot represent s.d.). e) Langmuir fitting curve for GET adsorption on MNPs. Red dots represent the adsorption measured on MNPs, and black 
line represents the nonlinear fitting of Langmuir isotherm. Values represent mean ± s.d. (n = 4).
Table 1. Physical characterization of GET–MNPs.
DH [nm]a) PDIb) Zeta potential  
[mV]
MNPs 320.9 ± 21.6 0.16 ± 0.04 −26.2 ± 6
GET–MNPs (4 nmol mg−1) 310.2 ± 12.8 0.16 ± 0.03 11.7 ± 1.5
GET–MNPs (8 nmol mg−1) 309.4 ± 11.7 0.16 ± 0.02 20.3 ± 0.8
The size and zeta potential of the bare and GET functionalized MNPs in water 
(dH2O) were measured using Malvern Nanosizer Nano ZS. Values represent 
mean ± s.d. (n = 6 independent experiments); a)Z-average hydrodynamic diameter 
extracted by cumulant analysis of the data; b)Polydispersity index from cumulant 
analysis.
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fraction of GET-T versus the free concentration in solution 
at equilibrium and nonlinear regression to adjust the experi-
mental data (Figure  1e; Figure S4, Supporting Information). 
Langmuir parameters are displayed in Table 2 (with Table S2 
in the Supporting Information).
This model provides an estimate reference concentration for 
MNP saturation with GET peptide, which would be important 
for future assays (indicating MNPs are saturated by GET-T at 
around 40  nmol mg−1 MNPs after a 10  min incubation).[47,48] 
Similarly, the equilibrium constant of 1.2  mL nmol−1 demon-
strates a relatively high binding efficiency of GET to the MNP, 
suggesting a reasonably stable NP formulation. Therefore, 
strong electrostatic interaction between the P21-8R GET peptide 
and dextran-coating of MNPs was capable of efficiently coating 
the MNP surface; which, except for charge, did not significantly 
change NP physical properties.
2.3. GET–MNPs Have Enhanced Intracellular Delivery Even with 
Low Amounts of Complexation
Previously, we have shown that exceptional levels of internali-
zation and cell-loading of iron oxide can be achieved by GET 
conjugation.[9,27] Next, we aimed to understand the level of 
binding required for this enhanced uptake activity, without 
compromising cell viability and proliferation. We assessed 
the ability of GET to enhance particle uptake in mamma-
lian cells (NIH3t3 mouse fibroblast cells) using a range of 
GET:MNPs ratios (Figure  2a). MNPs and GET–MNPs were 
delivered to cells overnight (16 h) and MNP-cell associa-
tion (that retained with the cell pellet after harvesting) was 
quantitatively assessed by inductively coupled plasma mass 
spectroscopy (ICP-MS) (Figure  2a; Table S3, Supporting 
Information). GET–MNPs significantly enhanced MNP cell 
association from 3.2 pg Fe per cell (50 µg of MNPs alone) to 
15 pg Fe per cell (50 µg of GET–MNPs). This was achieved 
at a GET:MNPs ratio of 4  nmol mg−1 MNPs, a dose that is 
tenfold lower than the estimated for particle saturation 
(44  nmol mg−1 MNPs). Uptake was progressively increased 
(in a linear fashion) with no further enhancement of interac-
tion or uptake beyond this dose of GET (4 nmol mg−1 MNPs). 
This data demonstrates only small amounts of GET peptide 
complexation is required for significantly enhanced MNP cell 
association.
For particle characterization and subsequent delivery to 
cells, we used this GET peptide amount as a standardized 
dose above the maximum effective dose but significantly 
below MNP saturation (4  nmol mg−1 MNPs). We chose 
this particular formulation looking to: a) obtain reproduc-
ible delivery efficiency; and b) ensure that small changes 
in interaction between GET and MNPs resulted in changes 
in particle uptake (delivery efficiency is significantly lower 
at doses below 4  nmol mg−1 MNPs; Table S3, Supporting 
Information). Furthermore, we confirmed that enhanced cell 
uptake through GET at these dosages does not have an effect 
on cell viability and proliferation (Figure S5, Supporting 
Information).
2.4. GET Complexation with MNPs Is Stable and Does Not 
Promote Aggregation in Serum Conditions
We were interested in further understanding the mecha-
nism underlying GET-mediated enhanced MNP uptake. In 
this context, it was important to confirm how the proper-
ties of both noncomplexed and GET–MNPs changed when 
exposed to the complex molecular environment of serum (in 
cell culture) and how that affected particle delivery. During 
the process of particle formulation and delivery, successive 
physicochemical changes on the MNPs by complexing GET 
peptides and further delivering in serum containing media, 
could potentially lead to a destabilization of the particle sur-
face and aggregation. It has been reported that aggregation 
could potentially increase cell association in certain cell lines, 
by adsorbing onto the cell membrane providing false posi-
tives on particle delivery.[49] Other reports, however, suggest 
that changes in particle size and shape due to aggregation 
could change the uptake pathway of the particles by cells.[50,51] 
Therefore, understanding aggregation is key to understand 
whether the reported enhanced delivery (Figure  2a) is effec-
tively mediated by GET directly or whether it could be attrib-
uted to precipitation of aggregates. Particle size distribution 
(measured by DLS) and zeta potential were analyzed immedi-
ately after particle complexation (day 1) and after 24 h incuba-
tion (day 2) in an attempt to mimic the behavior of particles 
over the delivery process in vitro (Figure  2b,c). MNPs and 
GET–MNPs in serum (the in vitro delivery conditions for 
cells) showed similar zeta potential distribution profiles with 
an average zeta potential of around −6  mV (Table S7, Sup-
porting Information), suggesting the interaction of both par-
ticles (MNP and GET–MNP) with negatively charged proteins 
in serum. There are no significant differences in particle size 
between MNPs and GET–MNPs (271.8 ± 9.64 nm and 276.7 ± 
8.58 nm, respectively; Table S4, Supporting Information). We 
carefully assessed the area under the curve (AUC) of the size 
distribution of i) main peak and ii) aggregate peak of MNPs 
and GET–MNPs (Figure 2c-i; Figure S5, Supporting Informa-
tion). Aggregates account for 2–5% of the total size distribu-
tion area, and there were no significant differences between 
aggregate formation in MNPs and GET–MNPs (Figure  2c-
ii). Furthermore, there were no significant differences in 
the size distribution of the main peak of immediately com-
plexed samples, or those at day 1 and day 2 postcomplexa-
tion (Figure  2c-i; Figure S6, Supporting Information). In 
summary, we found no differences in particle size or distri-
bution for MNPs and GET–MNPs after prolonged incubation 
in cell culture conditions. Therefore, our analyses suggest 
Table 2. Langmuir parameters for GET-T adsorption on MNPs.
Smax [nmol mg−1] K [mL nmol−1] SSR [nmol2 mg−2]
GET–MNPs 44 ± 8.6 1.2 ± 0.2 2.0 ± 2.5
Table shows parameters of adsorption Smax (maximum concentration of GET that 
can adsorb onto 50 µg of MNPs), the constant of adsorption K, and the sum of 
squared residuals (SSR) corresponding to the Langmuir fitting curves displayed 
in Figure S4 and Table S2 in the Supporting Information. Values represent mean ± 
s.d. n = 4 independent experiments.
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that GET-mediated enhanced particle uptake was not signifi-
cantly driven by progressive changes in particle charge, size, 
or aggregation.
2.5. GET–MNP Uptake and Not Complexation Is Directly 
Influenced by Heparin
Our proposed uptake mechanism for the GET system is 
based on the interaction of GET peptides with GAGs present 
on the cell membrane; this interaction in the presence of a 
CPP triggering the start of uptake by endocytotic processes 
(Figure  2d).[27] We assessed MNP delivery at increasing con-
centrations of heparin, which has been shown to serve as 
a competitive inhibitor of cell uptake by GET.[27] Heparin is 
a soluble highly sulfated and specific form of heparan sulfate 
generated by mast cells and has been previously used as a GAG 
competitor.[52] Heparin inhibits GET-mediated cell association 
by 93% (from 99.6% of particle uptake at 0.1 µg mL−1 heparin 
to 6.5% of particle uptake at 1 µg mL−1 heparin) (Figure  2e). 
Noncoated MNP uptake remains unaffected by even the 
highest concentration of heparin. Prussian Blue staining con-
firms the same trend and demonstrated uniformity across 
all cells tested (Figure S7, Supporting Information). It was 
unclear as to whether heparin-mediated inhibition was medi-
ated by competing and removing the GET peptide:MNP elec-
trostatic coating. This was important to determine as it could 
be argued that the decrease in cell association could be due to 
heparin destabilizing GET:MNPs interaction, causing peptide 
detachment from the MNPs and hence minimizing cell uptake 
Figure 2. Enhanced MNPs uptake is mediated by cell surface GAG. a) Iron cell association in NIH3t3s in the presence of MNP (50 µg) and increasing 
concentrations of GET (0.5, 1, 2, 4, 8, 20, and 40 nmol of GET mg−1). Iron cell association was measured by ICP-MS. Values represent mean iron 
association per cell ± s.d. (n = 6). b) Zeta potential of particles 50 µg incubated with 4 nmol mg−1 GET. Zeta potential was measured in 10% FCS. 
MNPs and GET–MNPs present similar charge distribution (n = 6 independent repeats, 3 subruns per repeat). c) Area under the curve (AUC) for the 
size distribution of MNPs and GET–MNPs of the i) main peak and ii) aggregates. Values represent mean area under the curve ± s.d. (n = 6). d) Sche-
matic representation of hypothesized mechanism for heparin interference in GET–MNPs interaction with the cells. e) Percentage of cell association in 
NIH3t3s of GET–MNPs at increasing concentrations of heparin (0, 0.01, 0.1, 1, and 10 µg mL−1 heparin). Percentage of cell association was calculated 
taking cell association in the absence of heparin as 100%. Values represent mean iron association per cell ± s.d. (n = 6).
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indirectly. In order to test this, red fluorescently tagged GET 
(GET-T)  was adsorbed onto MNPs and then incubated with 
increasing concentrations of heparin (Figure S8, Supporting 
Information); assessing the amounts released from the MNP by 
fluorometry. The data demonstrates that heparin does not have 
a significant effect on the amount of GET desorbed from MNPs 
compared to control (phosphate-buffered saline; PBS) even 
up to concentrations as high as 100 µg mL−1, which prevented 
any enhancement of uptake by GET coating in the cell assays. 
Taken together, these results suggest that heparin inhibits GET-
enhanced uptake of MNPs at the level of the cell membrane 
interaction and that the presence of GAGs in the cell surface is 
likely required for the enhanced particle association mediated 
by GET. This agrees with our more rigorous analyses in the 
studies that originally described GET delivery.[27]
2.6. GET Mediated Enhanced MNP Cell Association Is Rapid 
and Not Dependent on Cell-Type
We showed GET-mediated enhanced NP-cell association at 
low peptide concentrations. Next, we aimed to demonstrate 
that GET enhanced NP delivery was not cell type dependent. 
GET–MNPs (4  nmol mg−1 MNPs) were delivered to NIH3t3s 
(fibroblasts), U87 (glioma), and hMSCs (mesenchymal stem 
cells). All cell types showed at least threefold increase on par-
ticle association in the presence of GET (Figure 3a). Prussian 
Blue staining confirmed the presence of intracellular iron in 
hMSCs (Figure 3b). MNP delivery was also performed in serum 
free conditions confirming similar uptake profiles as that seen 
in protein-rich conditions (Figure S9, Supporting Information). 
Interestingly, the cell types behaved differently in the presence 
of serum; however, GET–MNPs had significantly enhanced cell 
association independent of cell type and media used.
2.7. GET Mediated MNP Cell Membrane Association Leads to 
Enhanced Uptake
To confirm that cell association indeed represented intracellular 
delivery and not simply extracellular membrane-associated 
MNPs, we performed microscopic analyses of embedded cell 
suspensions to assess MNP localization. Dual beam (focused 
ion beam-scanning electron microscopy; FIB-SEM) images 
of individual BV2 cells (immortalized murine microglial cell 
line) showed localization of internalized MNP aggregates in 
large clusters (≈500–1000  nm) around the cell nucleus con-
firming perinuclear accumulation of MNPs in endosomal vesi-
cles (Figure 3c). Similarly, TEM images of NIH3t3s after 24 h 
delivery of MNPs (Figure S10, Supporting Information) show 
accumulation in intracellular vesicular structures that resemble 
endosomes.
2.8. Extracellular Membrane Associated GET–MNPs Are Rapidly 
Internalized
Understanding the kinetics of MNP uptake was considered 
essential to further characterize GET mediated enhanced 
delivery. Iron content of the delivery media (including washes 
and trypsin; termed non-cell associated) and iron content 
within cells (after washing and trypsinization, representing 
just the cell pellet; termed cell associated) were analyzed at 
0.5, 2, 4, 6, and 24 h postdelivery of MNPs and GET–MNPs 
(Figure  3d). MNP uptake in cells is a process determined 
by factors such as flux across the cell membrane, endosome 
dynamics, and vesicular transport toward lysosomes. At early 
time points these processes are mainly considered to be con-
centration dependent and intracellular concentration of MNPs 
should appear to increase almost linearly. However, at later 
time-points, energy depletion and decrease in the number of 
endocytosis domains from the cell surface account for linearity 
deviation and eventually reach a steady state of uptake con-
centration.[53] This is the case for all our uptake experiments 
where for the first 4 h the concentration of iron associated with 
cells increased linearly with time, this independent of initial 
particle concentration or particle type (MNP or GET–MNPs) 
(Figure  3d). Linear approximation was calculated using the 
iron uptake interval between 0.5 and 4 h as it had been previ-
ously reported (Figure S11, Supporting Information).[54] There 
are significant differences in the slope of the curves (kinetic 
constant), which were proportional to the dose and signifi-
cantly higher for GET–MNP (Table S6, Supporting Informa-
tion). After 4 h, the concentration of iron in the cells against 
time starts to deviate from linearity (with larger deviations for 
the higher particle doses) toward a logarithmic fit, where the 
concentration of MNPs per cell remains almost constant up 
to 24 h. This kinetic model suggests that the final concentra-
tion of iron in the cells is mostly determined by the cellular 
uptake that takes place within the first 4 h. Significantly dif-
ferent kinetic constants of GET mediated delivery suggest that 
uncoated MNP uptake is not mediated by the same receptors 
(Table S6, Supporting Information). Our kinetic analyses simi-
larly confirms significant differences in final concentrations 
of iron cell association for MNPs and GET–MNPs as strong 
evidence for this. Physicochemical properties and concentra-
tions were the same for both experiments, almost identical 
sizes and charges in the presence of serum, so that only dif-
ferent cell surface binding/receptors and uptake mechanisms 
would account for different final uptake concentrations.[54,55] 
As expected the iron concentration in extracellular media 
decreases overtime inversely proportionally to the uptake of 
iron by cells providing an important technical control (Figure 
S12, Supporting Information).
2.9. Intracellular GET–MNPs Are Not Significantly Exported or 
Rapidly Degraded
Iron recycling, being iron secreted extracellularly from cells 
after uptake, was analyzed up to 4 days postdelivery. Our data 
showed no significant differences in the pattern of iron recy-
cling of cells incubated with MNPs or GET–MNPs, and the 
percentage exported was in all cases below 5% over the 3 days 
assessed postdelivery (Figure S13, Supporting Information). 
These results were consistent with the literature, and add to the 
argument that GET–MNPs are internalized and are not exocy-
tosed or degraded rapidly inside of cells.[56]
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2.10. GET Enhanced MNP Delivery Is Not Affected by Serum or 
Plasma Protein Corona
After characterizing the mechanism of enhanced MNP uptake 
mediated by GET peptide complexation, we wanted to further 
assess the effect of extracellular microenvironmental condi-
tions on the interaction of MNPs with cell membranes and 
their subsequent intracellular uptake. Importantly, all in vitro 
experiments presented so far had been performed in the pres-
ence of serum proteins (growth media containing 10% fetal 
calf serum; FCS, termed GM). It has been reported that tar-
geting systems can lose uptake efficiency, and can be even 
negated when employed in the presence of serum compared 
to delivery in serum-free media (Figure  4a).[19,57,58] Plasma 
is the fluid component of blood devoid of cells and platelets 
but has high concentrations of fibrinogen and other clotting 
agents, while serum is clotted plasma depleted of these com-
ponents.[59] Interestingly some studies use serum and plasma 
addition interchangeably when testing the effect of biological 
milieu on NPs, however, recent research has shown significant 
Figure 3. GET–MNPs have enhanced cell uptake in vitro. a) Iron cell association after delivery of 50 µg MNPs or GET–MNPs. Particles were delivered 
to: human mesenchymal stem cells (hMSCs), human glioblastoma cells (U87), and mouse embryonic fibroblasts (NIH3t3s). Iron cell association 
was measured by ICP-MS. Values represent mean iron association per cell ± s.d. (n = 6, ****p < 0.0001 Sidak’s multiple comparisons test, compared 
to MNPs alone). b) Representative light microscopy images of Prussian Blue iron-stained hMSCs treated with 50 µg MNPs or 50 µg MNPs–GET for 
12 h. When MNPs are delivered without GET, the iron staining is localized mainly around the cells. MNPs are taken into hMSCs most efficiently when 
delivered with GET (GET–MNPs). Circular image of entire well (scale bar: 50 µm). c) FIB-SEM images of individual BV2 microglial cells show the pres-
ence of dense agglomerates of MNPs inside the cell. BV2s were treated with 500 µg GET–MNPs (estimated 50 pg Fe per cell). Scale bars: i) 5 µm; ii) 
4 µm; iii) 500 nm. d) Iron cell association for i) naked MNPs delivery and ii) GET–MNPs over time in NIH3t3s at increasing dosages of MNPs (20, 50, 
and 80 µg). Iron content in the cells was measured 0.5, 1, 2, 4, 6, and 24 h postdelivery using ICP-MS. Values represent mean percentage of iron cell 
association ± s.d. (n = 6).
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Figure 4. GET–MNPs have enhanced uptake in vitro in the presence of plasma. a) Schematic of hypothesized GET–MNPs interaction in the pres-
ence of plasma proteins. b) Iron cell association after overnight delivery of MNP and GET–MNPs in serum free media (none), 10% FCS v/v in 
water (FCS), and 5% plasma v/v in water (plasma). Iron content was measured by ICP-MS. Values represent mean iron cell association per cell 
± s.d. (n = 6, **p < 0.01 Tukey’s multiple comparisons test, compared to FCS). c) Representative light microscopy images of Prussian Blue iron-
stained NIH3t3s treated with 50 µg MNPs or 50 µg MNPs–GET (4 nmol mg−1) for 12 h in serum free media (none) and at 5% plasma (plasma) 
(circular image is of entire well). Scale bar: 50 µm. d) Physicochemical characterization of GET–MNP in the presence of plasma proteins. i) The 
apparent diameter of MNPs and GET–MNPs in water is shown for reference (n = 6 independent repeats, 3 subruns per repeat, error bars in the 
close-up plot represent s.d.). ii) Zeta potential distribution of MNPs and GET–MNPs in 5% plasma v/v in water. The zeta potential of MNPs and 
GET–MNPs in water is shown for reference (n = 6 independent repeats, 3 subruns per repeat). e) Iron cell association after delivery of preconju-
gated GET–MNPs. GET–MNPs were formulated and incubated for 0 (control), 4, 8, 24, and 48 h in SFM or GM containing 10% FCS v/v (FCS). 
Iron content in the cell was measured 24 h postdelivery by ICP-MS. Values represent mean iron association per cell ± s.d. (n = 6, ***p < 0.001, 
Sidak’s multiple comparison test).
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differences between plasma and serum in terms of protein 
corona composition.[60,61]
It was therefore important to assess the differences in par-
ticle size and cellular uptake between the two milieus: plasma 
(unclotted containing fibrinogen and other factors) versus 
serum (clotted and lacking fibrinogen). Initially, unlike for 
serum or serum albumin, we found it technically difficult to 
coat and purify MNPs away from plasma without obtaining a 
significant degree of aggregation either using centrifugation or 
a static magnet (data not shown), which made delivery very var-
iable and difficult to reproduce. Furthermore, delivery and char-
acterization assessments were precluded in 100% plasma, as 
we found pure plasma significantly affected cell viability in cul-
tured lines, inhibiting the reproducibility of the delivery data.
MNPs and GET–MNPs were delivered in serum-free media 
(SFM, no protein), 5% plasma (see “MNP delivery in plasma” 
in the Experimental Section and Figure S14 and Table S7 in 
the Supporting Information) and 10% FCS (GM) incubation 
experiments with NIH3t3 cells (Figure 4b,c). GET peptide com-
plexation significantly and consistently enhanced MNP uptake 
regardless of media protein content. Delivery of GET–MNPs 
in plasma conditions was minimally but significantly lower 
than in serum free or serum-containing media. This could be 
attributed to the effect of plasma on cells directly but minimally 
affecting uptake.
2.11. Plasma Coronas Only Generate Subtle Changes in 
GET–MNP Physicochemical Properties
So far, significant emphasis was placed on the full characteriza-
tion of the GET–MNP interaction prior to delivery experiments 
but very little characterization had been undertaken within a 
cell culture or in vivo microenvironment. The composition of 
most biological media (containing serum or plasma proteins 
and different ions) has the potential to alter MNP surface prop-
erties. For instance, dissolved ions may neutralize charged 
chemical groups on the particle surface and favor an exchange 
process between molecules in solution and the surface associ-
ated molecules.[62] To confirm the physicochemical properties in 
more biologically relevant conditions, we assessed particle size, 
charge, and size distribution in plasma. Both MNPs and GET–
MNPs retained stability, with minimal changes in particle size 
or size distribution with incubation in 5% plasma compared to 
water (Figure  4d-i; Figure S15 and Tables S8–S10, Supporting 
Information). Interestingly, there were small but significant dif-
ferences in size between uncoated MNPs incubated in plasma 
and serum, suggesting a difference in the protein corona 
formed. Size differences were not observed for GET–MNPs 
(Table S8, Supporting Information). Similarly, to what was pre-
viously observed in serum, the presence of plasma proteins 
and ions significantly affected the particle charge, giving both 
MNPs and GET–MNPs identical negative charges (around 
−10 mV) (Figure 4d-ii). These findings have been described in 
literature suggesting that the formation of serum or plasma 
protein coronae leads to a normalization of the particle zeta 
potential.[63] When assessing aggregate formation over longer 
incubation periods in the presence of plasma (Figure S15e,f, 
Supporting Information), we observed a significant increase in 
MNPs aggregation and some loss of colloidal stability on day 
2, however there were no significant differences in aggregation 
between MNPs and GET–MNPs that could account for the dif-
ferences in cell uptake observed. Finally, seeking to further con-
firm the stability of the particles in serum, we preconjugated 
GET–MNPs and incubated them for up to 2 days (48 h) in SFM 
or GM. GET–MNPs were then delivered to cells overnight and 
cell association was quantified by ICP-MS (Figure 4e; Table S9, 
Supporting Information). Interestingly, GET–MNPs retained 
their full delivery efficiency for up to 48 h only when they were 
incubated in GM.
These results suggest that regardless of differential inter-
action of plasma proteins with MNPs and GET–MNPs, the 
activity of GET peptide is significantly retained on MNPs and 
still promotes enhanced intracellular particle uptake. Addition-
ally, serum proteins maintained GET–MNPs enhanced uptake 
over time, suggesting that protein coronae could play a role in 
stabilizing GET–MNPs in vitro.[64] Importantly, this data also 
confirms that positive charge is not absolutely required for the 
enhanced endocytosis mediated by GET to occur.[27]
2.12. Rapid, Specific, and Evolving Protein Corona Formation on 
GET–MNPs
In order to qualitatively confirm the formation of plasma pro-
tein coronas on MNPs and GET–MNPs, we exposed them to 
pure human plasma for 10 min, rapidly removed and washed 
away excess unbound protein by centrifugation, and ran sam-
ples directly on sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) gels. Denaturing electrophoresis 
revealed similar protein composition of the protein corona 
formed on MNPs and GET–MNPs; however, there were subtle 
differences in presence of some bands and band intensity when 
compared to whole plasma protein species (Figure 5a).
To gain a deeper insight of the effect of GET on the protein 
corona formation on MNPs, we used label-free snap-shot pro-
teomics using liquid chromatography mass spectroscopy (LC-
MS). The composition of the protein corona was assessed at 
two different time points to determine whether exposure time 
(acute, 1  min; chronic, 30  min) had an effect on the protein 
profile. There were no differences in the number of proteins 
identified between the two exposure times (167 proteins). This 
agrees with previously published research which reported that 
out of the thousands of proteins present in plasma only a few 
tens of proteins bind to NPs at significant quantities (>1 mol-
ecule per single MNP).[24,65]
Further analysis showed that negatively charged proteins at 
physiological pH (isoelectric point between 5 and 7) represent 
the majority of the corona components for both MNPs and 
GET–MNPs, irrespective of the particle initial surface charge 
or exposure time (Figure  5b-i). This finding is in accordance 
with the previously reported zeta potential results that show 
that NPs exposed to plasma present an overall negative charge 
irrespective of their original charge (Figure  4d; Table S8, Sup-
porting Information). These results once again reinforce the 
hypothesis that the overall charge of NPs is not a driving factor 
in the uptake process, and suggest that despite protein corona 
formation, GET is still available and able to interact with the 
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cell surface mediating endocytosis.[25,63,64,66] Evolution of pro-
teins over time follows similar patterns in MNPs and GET–
MNPs (Figure 5b) indicating a strong interaction of plasma pro-
teins with the dextran on the particle surface.[67] This suggests 
that for the most part, the kinetics of those interactions are not 
affected by the presence of GET peptide.
We examined the most abundant proteins forming coronae 
on MNPs and found differences among the top 15 most abun-
dant proteins forming MNPs and GET–MNPs coronas after 
1 and 30  min incubation; this was significantly different to 
analyses of plasma alone (Table  3; Tables S11 and S12, Sup-
porting Information). Data indicated an enrichment of certain 
plasma proteins within the MNP protein corona. Prothrombin 
is seen to be more commonly abundant in GET–MNPs than in 
MNPs (after 1 and 30 min of exposure). We compared the rela-
tive abundance of the proteins present in the protein corona of 
MNPs and GET–MNPs in order to identify proteins that were 
differentially present in the protein coronae (Figures S17 and 
S18, Supporting Information). We found that prothrombin 
(accession number: P00734) and vitamin K-dependent protein S 
(accession number: P07225) were significantly more abundant 
in GET–MNPs after 1 min exposure. After 30 min incubation, 
immunoglobulin heavy constant gamma (accession number: 
A0A087WV47) and prothrombin were significantly more abun-
dant in the protein corona of GET–MNPs compared to MNPs. 
We were not able to identify any proteins that were significantly 
enriched in the protein corona of MNPs alone. The consistent 
enrichment of glycoproteins in GET–MNPs indicates the for-
mation over time of a specific corona tailored by the GAG-
binding domain in GET peptide.
Interestingly, the protein corona evolution over time could 
corroborate previous findings suggesting that protein coronae 
are formed of two layers. The first layer (most internal) is 
hypothesized to be formed of biomolecules that are more tightly 
bound to the particle (termed hard corona), and an outer layer 
that interacts more loosely with the particle surface and inter-
acts more readily with the environment (termed soft corona)[65] 
which are the most evolving constituents.
Figure 5. Specific GET–MNP protein corona formation by SDS-PAGE and LC-MS. a) Separation of plasma proteins adsorbed on MNPs and GET–MNPs 
after 30 min incubation on 12% SDS-PAGE gel. Molecular mass and sample characteristics are indicated. b) Classification of corona proteins identified 
by LC-MS on MNPs and GET–MNPs after 1 and 30 min exposure to plasma. Proteins were classified according to i) calculated molecular weight, ii) 
isoelectric point, and iii) functional grouping. Relative percentages of protein abundance are shown (n = 2, independent experiments).
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Even though proteomic analyses demonstrated only minimal 
differences in the protein coronae formed, it is important to 
remember that specific plasma proteins have dedicated cell 
surface receptors in order to mediate their biological functions. 
The successful enhancement of MNP uptake in the presence 
of GET peptide complexation indicates that the affinity of GET 
peptides for GAGs presented on the cell membrane is greater 
to or compatible with other interactions elicited by the plasma 
molecules that form its protein corona.[25]
2.13. GET–MNP Corona Prevents Hemotoxicity and Aggregation
The biological effects of the plasma protein corona on GET–
MNPs were demonstrated on human erythrocytes (red blood 
cells; RBCs) since they are present in high concentrations in 
blood and are likely to be one of the first cell-types that interact 
with NPs as they enter the blood system in several biothera-
peutic applications.[68]
Human erythrocyte aggregation and cell morphology were 
assessed after exposure to GET–MNPs for 5, 15, 30, and 60 min 
in saline (PBS) or human plasma. Cells were also incubated 
with MNPs or GET peptide alone, and compared to Lipo-
fectamine 2000 (commercial transfection agent, Life Technolo-
gies). Time-course experiments assessing aggregation of eryth-
rocytes were conducted in both PBS and plasma (Figures S19 
and S20, Supporting Information, respectively). No significant 
changes in cell morphology were observed with MNPs or GET–
MNPs (Figures S19 and S20, Supporting Information). Cell 
morphology was immediately (<5  min) affected after incuba-
tion with Lipofectamine 2000 in PBS (Figure S19, Supporting 
Information). Interestingly, GET peptide alone in high concen-
tration progressively induced cell morphological changes over 
time in PBS (Figure 6a; Figure S19, Supporting Information). 
GET peptide-induced cell morphology could potentially be 
mediated by the interaction of the peptide with glycoproteins 
present in the erythrocyte cell membrane.[69] However, these 
changes in morphology were not observed when GET was 
adsorbed onto the MNPs (GET–MNPs) or in the presence of 
plasma. Additionally, the difference in osmolarity between the 
plasma and PBS could account for some of these morpholog-
ical changes in erythrocytes.[70]
No significant effects in aggregation or cell morphology were 
observed in human plasma except for Lipofectamine 2000, 
which progressively induced cell aggregation in the form of 
stacks, this phenomenon known as Rouleaux aggregation[71] 
(Figure S20, Supporting Information). This is associated with 
the presence of fibrinogen; however, other macromolecules 
such as dextran have also been reported to induce this phenom-
enon. Rouleaux aggregation is reversible, but in certain cases, it 
can lead to erythrocyte sedimentation and can be an indicator 
of disease.[71] The mechanism underlying this aggregation pro-
cess is still not well understood, however, macromolecules in 
solution seem to play a role as bridging agents between adja-
cent erythrocytes.
We further investigated the effect of the GET peptides and 
MNPs in erythrocyte cell lysis (hemolysis). The percentage of 
erythrocyte lysis was calculated compared to the effect of Triton-
X 100 (1% v/v), which permeabilizes and ruptures erythrocyte 
cell membranes (Figure  6b; Figure S21, Supporting Infor-
mation). Lipofectamine 2000 was analyzed as a control com-
mercially available transfection reagent. After 30  min, MNPs, 
GET, and GET–MNPs have similar low effect on hemolysis in 
PBS. Rapid corona formation in plasma efficiently prevented 
hemolysis for MNP and GET–MNP incubated erythrocytes 
(Figure 6b). Our data therefore demonstrates that soluble GET 
or GET–MNPs do not create aggregation or lysis of erythrocytes 
in the presence of the endogenous blood protein complexity 
provided by serum or plasma.
3. Conclusions
Our study demonstrates that GET peptide functionalized 
MNPs are capable of significantly enhancing MNP cell 
uptake in serum and plasma conditions (by up to eightfold). 
This increase in uptake was not due to aggregate formation 
and was mediated by GET-heparan sulfate interactions. Fur-
thermore, in a physiologically relevant environment, highly 
complex protein coronas are rapidly formed on GET–MNPs. 
These coronae evolve but do not dramatically change over 
time. In addition to this, we found that even if most corona 
proteins coating MNPs and GET–MNPs are the same, there 
are subtle differences in the relative abundance of the pro-
teins present, as well as a small number of specific proteins 
on GET–MNPs. This suggests that GET peptides can direct 
some plasma protein binding and subtly change the protein 
coronae formed.
We are aware that this study has some limitations and 
future more in depth analysis of the MNP protein corona 
Table 3. Top 15 most abundant corona proteins (NSAF) after 1 min of 
plasma exposure.
MNPs GET–MNPs
1 Apolipoprotein A-I Apolipoprotein A-I
2 Serum albumin Serum albumin
3 Fibrinogen gamma chain Prothrombina)
4 Apolipoprotein C-III Ig kappa chain C region
5 Fibrinogen beta chain Fibrinogen gamma chain
6 Apolipoprotein C-I (fragment) Fibrinogen beta chain
7 Ig kappa chain C region Apolipoprotein C-III
8 Apolipoprotein A-II Serotransferrin
9 Serotransferrin Apolipoprotein A-II
10 Apolipoprotein E Apolipoprotein C-I (fragment)
11 Fibrinogen alpha chain Transthyretin
12 Transthyretin Fibrinogen alpha chain
13 Apolipoprotein A-IV Apolipoprotein E
14 Kininogen-1 Apolipoprotein A-IV
15 Ig lambda-2 chain C regions 
(fragment)
Vitamin K-dependent protein Za)
The majority of proteins identified are common for MNPs and GET–MNPs; a)Most 
abundant proteins in GET–MNPs that are not present in MNPs are glycoproteins. 
n = 2 independent experiments.
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development over time may be needed in order to better pre-
dict the behavior of the particles in vivo. Understanding how 
heparan sulfates can affect corona formation and retention will 
help understanding of the mechanism through which GET–
MNPs can still significantly interact with cell membranes and 
internalize. Another important factor to be assessed is the long-
term stability of GET–MNPs in the presence of plasma, and 
the effect of plasma salts in the interactions between GET and 
MNPs. Further work should also consider whether the effect of 
plasma on preventing erythrocyte lysis is due to the presence of 
extra protein bulk in media, or whether plasma proteins play a 
specific role in erythrocyte protection. In addition, the effect of 
GET peptides and coated MNPs should be assessed with other 
blood components (such as thrombocytes) and directly deliv-
ered in vivo.
Our study is significant, since there appears to be a division 
in the literature on the effect of protein coronae on function-
ality and specificity of cell targeting molecules in biologically 
relevant environments. Here our findings confirm that the 
presence of protein corona on GET–MNPs does not signifi-
cantly affect the enhancement of particle uptake. This dem-
onstration represents a stepping-stone to further develop 
GET–MNPs into a platform technology for future drug delivery 
applications in nanomedicine. Finally, this study provides us 
with a better understanding of how protein corona can affect 
biological function.
4. Experimental Section
Physicochemical Analysis: Nanomag-D MNPs (Fe3O4 core; 250  nm; 
product code 09-02-252) were purchased from Micromod (Germany). 
The size and zeta potential of the bare and GET functionalized 
magnetic nanoparticles were measured in water (distilled H2O) using 
Malvern Nanosizer Nano ZS. Values represent mean ± standard 
deviation (s.d.).
DLS: Measurements consisted of 3 repeats (12–15 subruns per 
repeat) of the same sample to estimate the error in the measurements. 
The measurements were recorded at room temperature. N refers to 
the number of repeats. To measure the aggregation behavior of MNPs, 
particle size was measured on day 1 (particle formation and delivery) 
and day 2 (end of particle delivery) looking to most accurately reproduce 
particle delivery to cells in vitro. Main peak area was calculated between 
0 and 1600  nm. Aggregate area was calculated between 3000 and 
7000 nm. AUC was calculated by GraphPad Prism v 7.03.
Zeta Potential: Measurements consisted of 3 repeats (12–15 
subruns per repeat) of the same sample to estimate the error in the 
measurements. The measurements were recorded at room temperature. 
Because zeta potential measurements were performed in an aqueous 
solution, the Smoluchowski approximation was used to calculate the 
zeta potentials from the measured electrophoretic motilities. N refers to 
the number of repeats. Sidak’s multiple comparisons test was used to 
determine significant differences between samples.
TGA: The amount of dextran polymer on the particle surface 
was determined by TGA (TA Instruments Q 6000 STD) in a nitrogen 
atmosphere. MNPs were dried overnight at 80  °C  before TGA 
measurements. 2–4 mg of particles were deposited into a platinum TGA 
pan. The sample was allowed to equilibrate inside the TGA furnace at 
room temperature, and then was ramped to 200  °C  at a rate of 15  °C 
min−1. The sample was held at 200 °C min−1 for 5 min, before ramping 
up to 600 °C at 15 °C min−1. Sample was held at 600 °C for 5 min before 
cool-down. The organic content of the sample was estimated as the 
mass loss occurring between 200  and 500  °C.  The fraction of mass 
that evaporates before 200  °C  is typically assumed to be low-boiling 
volatiles (such as solvents, adsorbed moisture, etc.) while the fact that 
sample mass begins to plateau around 500 °C is taken to indicate that 
the organic has combusted and only the inorganic core of particles 
is left behind. The fraction of organic phase was calculated as the 
ratio between mass lost between 200  and 500  °C  over the total mass 
at 200 °C.
Protein Adsorption—GET Adsorption: GET peptide (P21-8R) was labeled 
with fluorescent variant of rhodamine, 5-carboxytetramethylrhodamine 
(5-TAMRA, Sigma, C2734), GET-T. The following solutions of GET-T 
were prepared in PBS: 0.025 × 10−9, 0.05 × 10−9, 0.1 × 10−9, 0.2 × 10−9, 
0.4 × 10−9, 1 × 10−9, and 2 × 10−9 m. GET-T. Solutions were incubated with 
50 µg mL−1 of Micromod dextran-coated MNPs under constant agitation 
for 10 min at RT (this incubation time was chosen based on experimental 
Figure 6. GET exposure does not trigger erythrocyte hemolysis. a) The effect of GET (0.4 nmol mL−1) on erythrocytes after 5 and 30 min in PBS and 
plasma. Scale bar: 20 µm. Close-up images were taken from Figures S19 and S20 in the Supporting Information. b) Hemolysis of erythrocytes. Eryth-
rocytes were exposed to 100 µg mL−1 MNPs (MNPs), 0.4 nmol mL−1 (GET), and 100 µg mL−1 GET-MNPs (4 nmol mg−1) in PBS or plasma for 30 min. 
They were also treated with Triton-x 100 (positive control for lysis) and Lipofectamine 2000 as comparison for transfection reagent. Values represent 
mean ± s.d. from 4 independent repeats from the same donor. Hemolysis was significantly affected by rapid protein corona formation in particles 
(n = 4, **p < 0.01, ***p < 0.001, ****p < 0.0001, Sidak’s multiple comparison test).
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in vitro delivery). MNPs were magnetically separated and supernatant 
was collected. PBS solution was used as a control. Protein concentration 
was measured using a plate reader excitation 546 nm, emission 579 nm 
(Infinite 200 PRO, TECAN). N  = 4, independent repeats. Standard 
curves were prepared for the tagged protein by plotting increasing 
concentrations of GET-T versus fluorescence.
Protein  Adsorption—Serum Albumin Adsorption: Solutions of FITC-
labeled bovine serum albumin (BSA) (Thermo Fisher, A23015) were 
prepared in PBS: 6.25, 12.5, 25, 50, 100, 150, and 200 µg mL−1. Solutions 
were incubated with 50  µg mL−1 of Micromod dextran-coated MNPs 
under constant agitation for 10  min at RT. MNPs were magnetically 
separated and supernatant was collected. PBS solution was used as 
a control. Protein concentration was measured using a plate reader 
excitation 488 nm, emission 532 nm (Infinite 200 PRO, TECAN). N = 6, 
independent repeats.
For GET peptides and BSA, standard curves were prepared for the 
tagged protein by plotting increasing concentrations versus fluorescence. 
Background fluorescence was subtracted both from the media (PBS) and 
MNPs only to account for particle background fluorescence. Isotherms 









where Cf is the solute concentration remaining in solution at equilibrium, 
S represents the adsorbed amount of solute at equilibrium, Smax is the 
maximum concentration of bound solute onto the MNPs, and K is 
the Langmuir’s equilibrium constant that describes the strength of 
interaction between solute and the particles surface.[44]
Briefly, a function was defined in Excel to minimize the value of the 
sum of squared residuals (SSR). In this context, a residual was defined 
as the difference between the observed data and the experimental data 
calculated using the Langmuir equation. Smax and K were adjusted to 
obtain a minimum value for SSR.
Protein  Adsorption—Conformational Assessment of Surface-Bound 
Proteins: Infrared analysis of surface-bound GET was conducted using a 
Thermo Fisher Scientific Nicolet iS50 FT-IR Spectrometer. Spectra were 
recorded at 4 cm−1 resolution with 36 scans being averaged, smoothed 
by 9 point adjacent averaging and curve fitted. OMNIC software was 
used to identify and analyze the spectra. Briefly, adsorption band 
regions in the amide 1 band were estimated from the wide range of 
literature: alpha helix (1646–1656 cm−1), beta sheets (1628–1640 and 
1669–1688  cm−1), unordered structures (1642–1652 cm−1), and turns 
(1659–1681 cm−1). Curve fitting methodologies were used as previously 
reported.[43] Statistical analysis was performed using Benjamini, Krieger, 
and Yekutieli t-test, with Q = 1%.
Protein Adsorption—Cell Culture: All cell lines were cultured at 37 °C 
in 5% CO2 in Dulbecco’s modified Eagle´s media (DMEM; Sigma), 
supplemented with 10% (v/v) FCS (Sigma), 4.5  g L−1 d-glucose, 2 × 
10−3 m l-glutamine, and 100 units mL−1 penicillin and 100 units mL−1 
streptomycin (Invitrogen).
MNP Delivery in Cell Culture: All particles used during the experiments 
were dextran-coated Nanomag-D MNPs (Fe3O4 core; 250  nm; 
Micromod, product code 09-02-252). Unless differently stated, MNPs 
used were COOH functionalized dextran-coated Nanomag-D MNPs. 
GET was chemically synthesized.
Cells were plated and incubated overnight until they reached 70–80% 
confluency. They were then treated, with nothing (media exchange), 
MNPs (50 µg mL−1), and GET–MNPs (50 µg mL−1, at 4 nmol GET mg−1 of 
MNPs unless otherwise specified). Particle delivery was done overnight 
unless otherwise stated. Particle delivery was normally performed in 10% 
FCS unless otherwise specified.
Heparin Competition: P21-8R (GET) was complexed at a low 
concentration (4 nmol mg−1 MNPs) to confirm the effect of heparin using 
MNPs unsaturated with complexed GET peptide. Before particle delivery, 
fresh media was replaced in the cells with increasing concentrations of 
heparin (0, 0.01, 0.1, 1, and 10 µg mL−1). After 1 h incubation, cells were 
then treated with MNPs (50 µg per well) and GET–MNPs (4 nmol mg−1). 
24 h postdelivery, cells were collected for analysis (ICP-MS and Prussian 
Blue staining).
MNP Delivery in Plasma: Due to the nature of the dextran, coating 
of the particles concentration or precipitation of the MNPs was not 
possible without obtaining a significant degree of aggregation. This 
made it very challenging to efficiently coat the MNPs with plasma and 
obtain consistent size particles. Delivery of particles and characterization 
in 100% plasma presented another challenge in terms of cell viability, 
affecting the reproducibility of the delivery. To overcome these technical 
issues, fluorescently labeled BSA was used. Albumin represents ≈50% 
of plasma protein content and therefore can be used as an estimate 
of the loading capacity of MNPs.[73] Langmuir modeling of the kinetics 
(generating isotherms; Figure S14, Supporting Information) was used and 
the amount of plasma needed to saturate the MNPs was extrapolated. 
Smax (the saturating amount) for albumin coating of MNPs was 
calculated to be around 318 µg mg−1 (Table S7, Supporting Information). 
Taking the density of plasma as 1.025  g mL−1, it was estimated that in 
order to saturate 50 µg MNPs (the amounts used for delivery), ≈31 µL 
(3.1% v/v) of a typical batch of human plasma was required. As Langmuir 
isotherm analyses are a simplified model of protein adsorption, the Smax 
value was used as a minimum approximation. For size, charge analysis, 
and in vitro delivery, 50 µL of plasma (5% v/v in 1 mL)  per 50 µg of 
MNPs was used unless otherwise specified.
Cell Viability Assays: After treatment with MNPs, cells were incubated 
for 24 h at 37  °C  with 5% CO2. After 24 h, cells were trypsinized and 
diluted in Trypan Blue (1:1) for cell count. Percentage of cell viability 
was calculated based on the total number of viable cells for each group 
compared to the untreated control. Half the trypsinized cells were plated 
again. Proliferation was measured as the cumulative number of viable 
cells every 24 h for 7 days.
FIB-SEM: After overnight treatment with GET–MNPs, BV2 cells 
were fixed in 2% glutaraldehyde solution for 2 h at 4  °C.  Cells were 
then washed in cacodylate buffer (pH 7.2) and treated with potassium 
ferrocyanide 2.5% osmium tetroxide 1% for 1 h at room temperature. 
Cells were dehydrated in increasing concentrations of acetone (30%, 
50%, 70%, 90%, and 100%). Images were taken using a Dual-Beam 
(Nova NanoLab 200, FEI Company) equipped with a Ga+ ion beam 
column, operating with a beam voltage of 30  kV and an ion current 
of 10 pA. SEM images were taken with an FEG column, working at 
5–10 kV and electron currents between 50 and 98 pA. Sequential cross-
sectioning of single BV2 cells was performed using the FIB and then 
SEM images were taken to assess the intracellular localization of 
MNPs.
TEM: After overnight treatment with GET–MNPs, NIH3t3 cells were 
fixed in 3% (w/v) glutaraldehyde in 0.1 m cacodylate buffer for 1 h and 
postfixed in 1% aqueous osmium tetroxide for 30  min. The samples 
were then dehydrated in a graded ethanol series and infiltrated with 
Transmit resin (TAAB, UK), and then allowed to polymerize for 48 h 
at 70  °C.  Semithin sections were cut (0.5  µm), using a Reichert-Jung 
ultramicrotome, and stained with 2% toluidine blue. Ultrathin sections 
were cut (100 µm) using the same equipment and collected on copper 
grids, which were then contrasted using 50% methanol uranyl acetate 
and Reynolds lead citrate. Imaging was performed on a Tecnai 12 
Biotwin TEM (FEI, USA) run at 100 kV.
Iron Qualitative Analyses and Subcellular Localization by Prussian Blue 
Staining: Cells were fixed for 20  min with 4% (w/v) paraformaldehyde 
(Sigma) at room temperature. Prussian Blue staining solution: 
potassium ferrocyanide (Sigma) was diluted in a solution of 2.5% 
(v/v) hydrochloric acid (HCl) in distilled H2O to a final concentration 
of 25  mg  mL−1 (Scientific Laboratory Supplies). Prussian Blue staining 
solution was added to the cells and incubated for 1 h. Stained cells were 
imaged using a Nikon Eclipse TS1000 light microscope.
Iron Quantification by Inductively Coupled Plasma Mass 
Spectrophotometry: MNPs were delivered as described above. After 
incubation overnight, the supernatant was removed and cells were 
washed twice with PBS. Cells were trypsinized and lysed in HCl 6 m, 
HNO3 (65%) for 2 h at room temperature for the degradation of the 
particles in order to release the Fe content. Samples were then diluted 
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in water in order to achieve a final acid concentration of less than 2% 
(w/v). A calibration curve was also produced at MNPs concentrations 
up to 50 µg mL−1 to account for possible matrix effects.
Diluted solutions were analyzed by ICP-MS (Thermo Fisher Scientific 
iCAP-Q; Thermo Fisher Scientific, Bremen, Germany). Elemental analysis 
of diluted solutions was undertaken by ICP-MS (Thermo Fisher Scientific 
iCAP-Q and iCAP-TQ; Thermo Fisher Scientific, Bremen, Germany). 
Samples were introduced (flow rate 1.2 mL min−1) from an autosampler 
(Cetac ASX-520) incorporating an ASXpress rapid uptake module 
through a perfluoroalkoxy (PFA) Microflow PFA-ST nebulizer (Thermo 
Fisher Scientific, Bremen, Germany). Sample processing was undertaken 
using Qtegra software (Thermo Fisher Scientific) utilizing external cross-
calibration between pulse-counting and analogue detector modes when 
required. Internal standards were introduced to the sample stream on 
a separate line via the ASXpress unit and included Ge (10 µg L−1), Rh 
(10 µg L−1), and Ir (5 µg L−1) in 2% trace analysis grade (Fisher Scientific, 
UK) HNO3. Fe external calibration standard (Claritas-PPT grade CLMS-2 
from SPEX Certiprep Inc., Metuchen, NJ, USA), in the range 0–100 µg 
L−1 (0, 20, 40, and 100 µg L−1) was employed. Phosphorus, boron, and 
sulfur calibration utilized in-house standard solutions (KH2PO4, K2SO4, 
and H3BO3). A collision-cell (Q cell) using He with kinetic energy 
discrimination (He-cell) to remove polyatomic interferences was used to 
measure Fe. Sample processing was undertaken using Qtegra software 
(Thermo Fisher Scientific). Results were reported back in ppb (µg L−1). 
Iron association per cell was calculated based on the doubling times 
of the respective cell lines to estimate total number of cells. Sidak’s 
multiple comparisons test was used to determine significant differences 
between samples.
SDS-PAGE Analyses: For determination of plasma proteins adsorbed 
onto the particles (MNPs and GET–MNPs), SDS-PAGE using Novex 
12.5% Tris-Glycine mini protein gel (Invitrogen) was used following the 
manufacturer’s instructions. Gels were stained with Coomassie blue 
(Invitrogen) and destained before imaging.
LC-MS and Snapshot Proteomics: Human plasma was obtained from 
Sigma (pooled human blood). MNPs and GET–MNPs were incubated 
in plasma for 1 and 30  min at 37  °C.  After incubation, particles were 
centrifuged (5 min at 14 000 × g) and separated from the plasma aided 
by a static field. Particles pellets were washed twice with PBS. Particles 
were then digested with trypsin and analyzed by liquid chromatography 
coupled with tandem mass spectrometry (LC-MS/MS) using either 
a 4000 Q-Trap (Applied Biosystems, Carlsbad, CA, USA) mass 
spectrometer.
Proteomics results were analyzed using Scaffold software. Key 
identification parameters were set to 95% protein threshold, minimum 
number of peptides 2, and peptide threshold of 95%. Quantitative 
analysis was done by NSAF. Proteins were then clustered based on size 
(molecular weight), isoelectric point, and protein family. Differential 
abundance of a protein was calculated as a function of protein relative 
abundance in nanoparticles/average of the relative abundance across 
all samples. N represents the number of independent experiments 
(each independent experiment was performed with a different plasma 
batch, with two experimental replicates per experiment).
Hematocompatibility Assays—Erythrocyte Aggregation: The impact 
of the GET–MNPs on erythrocyte aggregation and hemolysis were 
analyzed as described.[24] Briefly, human blood sample was purchased 
from NHS. Blood was transferred into tubes and centrifuged at 
5000 × g for 5  min. The cell pellet was washed twice with PBS. 
To quantify aggregation, 6  ×  105 erythrocytes were mixed to final 
concentrations of 100  µg  mL−1 GET-MNPs (4  nmol mg−1). After 
incubation under constant shaking at 37  °C  for 5, 15, and 30  min, 
cell aggregation was evaluated using Nikon Eclipse TS1000 light 
microscope. As negative control for aggregation, erythrocytes were 
treated with either PBS or plasma alone.
Hematocompatibility Assays—Hemolysis: To assess the hemolytic activity 
of GET–MNPs, 6 × 106 erythrocytes were mixed to final concentrations of 
100 µg mL−1 MNPs GET–MNPs (4 nmol mg−1). Cells were also mixed with 
MNPs only (100 µg mL−1) and GET only (0.4 nmol mL−1). After incubation 
for 5, 15, and 30  min, samples were centrifuged at 5000 × g for 5  min. 
The supernatant was collected and hemoglobin content was analyzed 
by spectrophotometry at 544  nm (Infinite 200 PRO, TECAN). PBS and 
plasma were used as controls. Results were expressed as percentage lysis 
taking Triton-x 100 as complete lysis (100%).
Statistical Analysis: For in vitro studies, n represents the number of 
biological repeats. Technical replicates refer to experiments carried 
out with different passage cells but identical experimental conditions. 
Data were presented as mean ± s.d. Significant differences between 
test groups were analyzed by two-way ANOVA. p values <0.05 were 
considered statistically significant. Data were analyzed by Prism 
statistical analysis software (GraphPad v. 7.03).
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